HIV/INFECTIOUS DISEASE TEST/TREATMENT IN SUBSTANCE ABUSE

药物滥用中的艾滋病毒/传染病检测/治疗

• 批准号: 6523131
• 负责人: Michelle A Lally
• 金额: $ 13.49万
• 依托单位: MIRIAM HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2000
• 资助国家: 美国
• 起止时间: 2000-09-25 至 2005-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6523131
• 关键词: AIDS /HIV diagnosis; HIV infections; Trichomonas; chlamydial disease; clinical research; clinical trials; communicable disease diagnosis; counseling; drug abuse therapy; gonorrhea; hepatitis B; hepatitis C; human subject; microorganism disease chemotherapy; protozoal infection; sexually transmitted diseases; substance abuse related disorder

DESCRIPTION: (Applicant's Abstract) Phase I of the proposed project will examine barriers to comprehensive HIV and other infectious disease testing and follow-up care among substance abusers at a short term (detox) substance abuse treatment center. In Phase II an intervention that includes comprehensive testing, counseling, medical deferral, and practical strategies to overcome barriers to follow up care will be designed and pilot tested. During Phase III, the intervention will be evaluated against the standard of care of offering HIV testing done through a randomized controlled trial. Three hundred and forty-four participants will be randomized to receive either the comprehensive testing and facilitated referral intervention which will offer testing for HIV, hepatitis B and C, and the STDs gonorrhea and chlamydia (and trichomonas for women only) or standard of care HIV testing alone and referral for further hepatitis and STD testing. Primary endpoints will be the number of tests performed, the number of test results received, and the degree of follow up medical care obtained for the two groups.

描述：(申请人摘要) 拟议项目的第一阶段将审查全面艾滋病毒和艾滋病的障碍 药物滥用者的其他传染病检测和后续护理 一个短期(戒毒)药物滥用治疗中心。在第二阶段和 干预措施包括全面测试、咨询、医疗延迟、 克服后续护理障碍的实用战略将是 设计并进行了试运行。在第三阶段，将对干预措施进行评估 根据提供艾滋病毒检测的护理标准，通过随机 对照试验。344名参与者将被随机分配 接受全面测试和促进转介 将提供艾滋病毒、乙肝和丙型肝炎以及性传播疾病检测的干预措施 淋病和衣原体(和滴虫仅限女性)或护理标准 单独进行艾滋病毒检测，并转介进行进一步的肝炎和性病检测。主要 端点将是执行的测试的数量、测试结果的数量 以及两组获得的后续医疗护理的程度。